SCHEMBL13344896

SCHEMBL13344896

Cc1cc2cc(OCCO)ccc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.60
PPARD Q03181 1/20 0.50
PDE3B Q13370 3/20 0.49
PDE3A Q14432 3/20 0.49
P2RY12 Q9H244 3/20 0.49
MAOA P21397 1/20 0.47
NR1I2 O75469 1/20 0.46
CYP2A6 P11509 1/20 0.46
KEAP1 Q14145 1/20 0.46
PDE2A O00408 2/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PDGFRB P09619 4/20 0.43
PDGFRA P16234 4/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12327788 0.85 AXL (0.62) AXLPPARDCYP2A6KEAP1KDM4E
SCHEMBL16756015 0.85 AXL (0.62) AXLPPARDCYP2A6KEAP1KDM4E
SCHEMBL22300369 0.84 AXL (0.65) AXLPPARDMAOACYP2A6KEAP1
SCHEMBL8292832 0.81 AXL (0.66) AXLPPARDPDE3BPDE3ACYP2A6
SCHEMBL13344928 0.81 PDGFRB (0.60) AXLPPARDMAOACYP2A6KEAP1
SCHEMBL5735637 0.81 AXL (0.57) AXLPPARDPDE3BPDE3AP2RY12
SCHEMBL28268326 0.80 AXL (0.55) AXLPPARDCYP2A6KEAP1KDM4E
SCHEMBL14218665 0.80 AXL (0.64) AXLPPARDCYP2A6KEAP1KDM4E
SCHEMBL13344938 0.80 AXL (0.51) AXLPPARDMAOACYP2A6KEAP1
SCHEMBL9272429 0.79 PPARD (0.52) AXLPPARDPDE3BPDE3AP2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A AXL 4418/4885PPARD 2080/4885PDE3B 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.